Prostate Cancer
The Clinical Trials Office at Ziekenhuis Aan De Stroom in Antwerp focuses on clinical research in prostate cancer, with studies addressing treatment decisions in both biochemical recurrence and high-risk disease.
- Salvage radiotherapy
- Androgen-deprivation therapy
- Anti-androgen therapy
- Radical prostatectomy
Its research activity includes comparative approaches to post-surgical management and the use of advanced treatment combinations for disease control.
Hormonal and Androgen Receptor-Targeted Treatment
The sponsor is involved in studies examining hormonal treatment strategies for prostate cancer, with attention to androgen receptor-directed therapies and combinations used alongside radiotherapy.
- LHRH agonists
- LHRH antagonists
- Apalutamide
- Darolutamide
These studies reflect interest in treatment selection across intensification and de-intensification approaches within localized and recurrent disease settings.
Radiotherapy and Multimodal Care
Clinical research at this site also centers on radiotherapy combined with systemic treatment, including strategies designed to improve disease control after prostate surgery and in patients with higher-risk disease features.
- Post-prostatectomy treatment
- Combined-modality therapy
- Local and systemic disease control
- Treatment intensification
The trial portfolio includes comparisons of treatment combinations intended to refine the role of radiation-based management in prostate cancer care.
Molecular Imaging and Disease Stratification
The sponsor contributes to research using PSMA PET/CT and other novel diagnostic radio- and molecular tracers to guide treatment planning in prostate cancer.
- PSMA PET-positive lesions
- Molecular tracers
- Metastasis-free survival
- Risk-adapted treatment selection
These activities connect imaging-based disease assessment with therapeutic decision-making in advanced and high-risk prostate cancer.
Quality of Life and Sexual Function
Patient-centered outcomes are a clear area of interest, including research on sexual function and quality of life during prostate cancer treatment.
- EPIC-26 sexual domain
- Quality of life indices
- Treatment tolerability
- Functional outcomes
These endpoints are used to evaluate how different prostate cancer treatment strategies affect daily functioning and patient experience.
